Peapod Lane Capital LLC Grows Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Peapod Lane Capital LLC boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 24.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 135,655 shares of the company's stock after acquiring an additional 26,802 shares during the quarter. Peapod Lane Capital LLC owned 0.36% of iTeos Therapeutics worth $810,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Balyasny Asset Management L.P. bought a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $218,000. BNP Paribas Financial Markets purchased a new stake in iTeos Therapeutics during the fourth quarter valued at $461,000. Virtu Financial LLC raised its stake in iTeos Therapeutics by 84.3% during the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after purchasing an additional 8,460 shares in the last quarter. US Bancorp DE grew its holdings in shares of iTeos Therapeutics by 40.1% in the fourth quarter. US Bancorp DE now owns 16,919 shares of the company's stock worth $130,000 after purchasing an additional 4,843 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of iTeos Therapeutics in the fourth quarter worth about $1,159,000. Institutional investors own 97.16% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on ITOS shares. Wells Fargo & Company restated an "equal weight" rating and issued a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Piper Sandler reissued an "overweight" rating and set a $12.00 price target (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Wedbush lowered shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and increased their price objective for the company from $10.00 to $12.00 in a research report on Wednesday, May 28th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $15.86.

iTeos Therapeutics Price Performance

NASDAQ ITOS traded up $0.06 on Friday, hitting $10.27. The company had a trading volume of 408,864 shares, compared to its average volume of 692,432. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13. The company's fifty day moving average price is $9.22 and its 200-day moving average price is $7.81. The company has a market capitalization of $393.15 million, a PE ratio of -3.38 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. On average, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Insider Activity at iTeos Therapeutics

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider directly owned 3,452,797 shares of the company's stock, valued at $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Hallal sold 38,228 shares of the stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.24, for a total value of $391,454.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,939,307 shares of company stock valued at $16,202,116. Company insiders own 12.50% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.